Junboytennis的个人主页 - 老虎社区

Junboytennis

Junboytennis

Check out Jun tennis academy

IP属地：未知

5关注

3粉丝

0主题

0勋章

2021-12-01

$PayPal(PYPL)$Zero positive catalyst

2021-11-24

$Futu Holdings Limited(FUTU)$Even with good earnings this stock might fall … without a doubt back to lows after today

2021-11-22

$Tiger Brokers(TIGR)$Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock. Example $PayPal(PYPL)$

2021-11-16

Good news

抱歉，原内容已删除

2021-11-08

$Tiger Brokers(TIGR)$short everyday lol

2021-11-05

Good news but this won’t move the candles up

@老虎国际:老虎国际率先成为新加坡交易所交易会员、清算会员及存托代理

2021-11-05

$Tiger Brokers(TIGR)$Seems like shorters want it at $2

2021-11-03

$PayPal(PYPL)$Just gotta wait for good news :)

2021-11-02

$Tiger Brokers(TIGR)$Slowly but surely

2021-11-02

$Tiger Brokers(TIGR)$Fight again today for positivity

2021-11-01

$Tiger Brokers(TIGR)$Hold with conviction.

2021-10-28

$Tiger Brokers(TIGR)$UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.

2021-10-26

$Tiger Brokers(TIGR)$The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term

2021-08-27

$Tiger Brokers(TIGR)$It’s a good company, it should be doing well, stock prices oversold

2021-08-16

$Tesla Motors(TSLA)$Goes down insanely with any tiny bad news.

2021-07-27

$Tesla Motors(TSLA)$Here we go again …

2021-07-19

$Pershing Square Tontine Holdings(PSTH)$Whata bad choice of stock to buy

2021-07-14

Isn’t it overvalued atm

抱歉，原内容已删除

2021-06-18

Great

抱歉，原内容已删除

2021-06-18

Rushing

Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3575032921579900","uuid":"3575032921579900","gmtCreate":1611965244035,"gmtModify":1637762544173,"name":"Junboytennis","pinyin":"junboytennis","introduction":"","introductionEn":"","signature":"Check out Jun tennis academy","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":5,"tweetSize":35,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":9,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":609596374,"gmtCreate":1638292492235,"gmtModify":1638292492235,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>Zero positive catalyst&nbsp;","listText":"<a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>Zero positive catalyst&nbsp;","text":"$PayPal(PYPL)$Zero positive catalyst","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609596374","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874832900,"gmtCreate":1637754442654,"gmtModify":1637754442654,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Even with good earnings this stock might fall … without a doubt back to lows after today&nbsp;","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Even with good earnings this stock might fall … without a doubt back to lows after today&nbsp;","text":"$Futu Holdings Limited(FUTU)$Even with good earnings this stock might fall … without a doubt back to lows after today","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874832900","isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875965738,"gmtCreate":1637595092281,"gmtModify":1637595092281,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock.&nbsp;Example <a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock.&nbsp;Example <a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>","text":"$Tiger Brokers(TIGR)$Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock. Example $PayPal(PYPL)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875965738","isVote":1,"tweetType":1,"viewCount":3355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871661259,"gmtCreate":1637065470770,"gmtModify":1637065470889,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871661259","repostId":"1196231262","repostType":4,"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845785121,"gmtCreate":1636368870973,"gmtModify":1636368871085,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>short everyday lol","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>short everyday lol","text":"$Tiger Brokers(TIGR)$short everyday lol","images":[{"img":"https://static.tigerbbs.com/91a03489b7b3ee9099c387b3083cface","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845785121","isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846434787,"gmtCreate":1636103506175,"gmtModify":1636103506234,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Good news but this won’t move the candles up&nbsp;","listText":"Good news but this won’t move the candles up&nbsp;","text":"Good news but this won’t move the candles up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846434787","repostId":"846574549","repostType":1,"repost":{"id":846574549,"gmtCreate":1636101163689,"gmtModify":1636128334016,"author":{"id":"36992157811200","authorId":"36992157811200","name":"老虎国际","avatar":"https://static.tigerbbs.com/801219a1b6ce93d3dd574afc3dcc9be9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36992157811200","idStr":"36992157811200"},"themes":[],"title":"老虎国际率先成为新加坡交易所交易会员、清算会员及存托代理","htmlText":"近日，知名互联网券商老虎国际（NASDAQ：TIGR）宣布获得新加坡交易所（SGX，以下简称“新交所”）四项资格认证，包括：新交所全资子公司中央托收私人有限公司（CDP）的清算会员及存托代理、&nbsp;新加坡交易所证券交易有限公司（\"SGX-ST\"）交易会员和新加坡交易所衍生工具交易有限公司交易会员（\"SGX-DT\"），成为全球率先获得新交所四项资质的互联网券商。 老虎国际创始人及CEO巫天华表示：“我们很荣幸能在互联网券商中率先获得新交所的四项资格认证。新加坡是公司国际化战略启程的第一站，我们十分看重新加坡市场并持续投入。获得相关资质将帮助老虎国际更好地融入新加坡本地金融基础设施，进一步提升客户星股交易体验。” 据悉，老虎国际获得相关资质后，在证券和衍生品交易下单执行阶段可以直连新交所，平台上的新加坡股交易清算将逐步迁移至其自研系统完成，同时客户资产保护将再度升级，满足全球新加坡股投资者更具个性化的交易需求，并进一步提高本地化运营效率。目前，老虎国际的前中后台均已实现自研，其技术闭环将为新加坡本地和全球星股交易客户提供更优质的服务。 进入新加坡市场一年多来，老虎国际凭借强大的技术实力、多元的产品矩阵、严谨的合规风控和快速响应的前中后台运营能力，迅速成为本地用户投资全球的一站式交易平台，用户仅通过一个账户即可完成美股、港股、A股通（沪港通/深港通）和星股（新加坡股）等全球多个重要金融市场的交易。 与此同时，老虎国际致力于为新加坡用户提供创新型的产品和服务，率先成为提供美、港、星股移动端IPO申购的互联网券商，获得本地用户信赖，交易活跃度持续提升。截至目前，老虎国际来自新加坡的入金客户已超过20万，在当地互联网券商中持续保持领先地位。 在持续服务新加坡个人投资者的同时，老虎国际不久前还宣布进军新加坡企业服务市场，与本地合作伙伴携手向新加坡金融机构提供技术解决方案，届时本地投","listText":"近日，知名互联网券商老虎国际（NASDAQ：TIGR）宣布获得新加坡交易所（SGX，以下简称“新交所”）四项资格认证，包括：新交所全资子公司中央托收私人有限公司（CDP）的清算会员及存托代理、&nbsp;新加坡交易所证券交易有限公司（\"SGX-ST\"）交易会员和新加坡交易所衍生工具交易有限公司交易会员（\"SGX-DT\"），成为全球率先获得新交所四项资质的互联网券商。 老虎国际创始人及CEO巫天华表示：“我们很荣幸能在互联网券商中率先获得新交所的四项资格认证。新加坡是公司国际化战略启程的第一站，我们十分看重新加坡市场并持续投入。获得相关资质将帮助老虎国际更好地融入新加坡本地金融基础设施，进一步提升客户星股交易体验。” 据悉，老虎国际获得相关资质后，在证券和衍生品交易下单执行阶段可以直连新交所，平台上的新加坡股交易清算将逐步迁移至其自研系统完成，同时客户资产保护将再度升级，满足全球新加坡股投资者更具个性化的交易需求，并进一步提高本地化运营效率。目前，老虎国际的前中后台均已实现自研，其技术闭环将为新加坡本地和全球星股交易客户提供更优质的服务。 进入新加坡市场一年多来，老虎国际凭借强大的技术实力、多元的产品矩阵、严谨的合规风控和快速响应的前中后台运营能力，迅速成为本地用户投资全球的一站式交易平台，用户仅通过一个账户即可完成美股、港股、A股通（沪港通/深港通）和星股（新加坡股）等全球多个重要金融市场的交易。 与此同时，老虎国际致力于为新加坡用户提供创新型的产品和服务，率先成为提供美、港、星股移动端IPO申购的互联网券商，获得本地用户信赖，交易活跃度持续提升。截至目前，老虎国际来自新加坡的入金客户已超过20万，在当地互联网券商中持续保持领先地位。 在持续服务新加坡个人投资者的同时，老虎国际不久前还宣布进军新加坡企业服务市场，与本地合作伙伴携手向新加坡金融机构提供技术解决方案，届时本地投","text":"近日，知名互联网券商老虎国际（NASDAQ：TIGR）宣布获得新加坡交易所（SGX，以下简称“新交所”）四项资格认证，包括：新交所全资子公司中央托收私人有限公司（CDP）的清算会员及存托代理、 新加坡交易所证券交易有限公司（\"SGX-ST\"）交易会员和新加坡交易所衍生工具交易有限公司交易会员（\"SGX-DT\"），成为全球率先获得新交所四项资质的互联网券商。 老虎国际创始人及CEO巫天华表示：“我们很荣幸能在互联网券商中率先获得新交所的四项资格认证。新加坡是公司国际化战略启程的第一站，我们十分看重新加坡市场并持续投入。获得相关资质将帮助老虎国际更好地融入新加坡本地金融基础设施，进一步提升客户星股交易体验。” 据悉，老虎国际获得相关资质后，在证券和衍生品交易下单执行阶段可以直连新交所，平台上的新加坡股交易清算将逐步迁移至其自研系统完成，同时客户资产保护将再度升级，满足全球新加坡股投资者更具个性化的交易需求，并进一步提高本地化运营效率。目前，老虎国际的前中后台均已实现自研，其技术闭环将为新加坡本地和全球星股交易客户提供更优质的服务。 进入新加坡市场一年多来，老虎国际凭借强大的技术实力、多元的产品矩阵、严谨的合规风控和快速响应的前中后台运营能力，迅速成为本地用户投资全球的一站式交易平台，用户仅通过一个账户即可完成美股、港股、A股通（沪港通/深港通）和星股（新加坡股）等全球多个重要金融市场的交易。 与此同时，老虎国际致力于为新加坡用户提供创新型的产品和服务，率先成为提供美、港、星股移动端IPO申购的互联网券商，获得本地用户信赖，交易活跃度持续提升。截至目前，老虎国际来自新加坡的入金客户已超过20万，在当地互联网券商中持续保持领先地位。 在持续服务新加坡个人投资者的同时，老虎国际不久前还宣布进军新加坡企业服务市场，与本地合作伙伴携手向新加坡金融机构提供技术解决方案，届时本地投","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846574549","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846330063,"gmtCreate":1636046810089,"gmtModify":1636046810258,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Seems like shorters want it at $2&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Seems like shorters want it at $2&nbsp;","text":"$Tiger Brokers(TIGR)$Seems like shorters want it at $2","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846330063","isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848050559,"gmtCreate":1635949303047,"gmtModify":1635949303163,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>Just gotta wait for good news :)","listText":"<a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>Just gotta wait for good news :)","text":"$PayPal(PYPL)$Just gotta wait for good news :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848050559","isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841994293,"gmtCreate":1635866844232,"gmtModify":1635866844232,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Slowly but surely","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Slowly but surely","text":"$Tiger Brokers(TIGR)$Slowly but surely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841994293","isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843513298,"gmtCreate":1635840937286,"gmtModify":1635840937341,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Fight again today for positivity&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Fight again today for positivity&nbsp;","text":"$Tiger Brokers(TIGR)$Fight again today for positivity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843513298","isVote":1,"tweetType":1,"viewCount":810,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849651672,"gmtCreate":1635754422475,"gmtModify":1635754422580,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Hold with conviction.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Hold with conviction.","text":"$Tiger Brokers(TIGR)$Hold with conviction.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849651672","isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854013842,"gmtCreate":1635409954996,"gmtModify":1635410387438,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.","text":"$Tiger Brokers(TIGR)$UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854013842","isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852398341,"gmtCreate":1635239465834,"gmtModify":1635239466002,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term&nbsp;","text":"$Tiger Brokers(TIGR)$The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852398341","isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":810470474,"gmtCreate":1629998316898,"gmtModify":1704954426218,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>It’s a good company, it should be doing well, stock prices oversold&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>It’s a good company, it should be doing well, stock prices oversold&nbsp;","text":"$Tiger Brokers(TIGR)$It’s a good company, it should be doing well, stock prices oversold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810470474","isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839366663,"gmtCreate":1629122799952,"gmtModify":1631890931942,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Goes down insanely with any tiny bad news.","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Goes down insanely with any tiny bad news.","text":"$Tesla Motors(TSLA)$Goes down insanely with any tiny bad news.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/839366663","isVote":1,"tweetType":1,"viewCount":493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809719213,"gmtCreate":1627392913632,"gmtModify":1631890931934,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Here we go again …","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Here we go again …","text":"$Tesla Motors(TSLA)$Here we go again …","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809719213","isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171000582,"gmtCreate":1626692568846,"gmtModify":1631889012837,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PSTH\">$Pershing Square Tontine Holdings(PSTH)$</a>Whata bad choice of stock to buy&nbsp;","listText":"<a href=\"https://laohu8.com/S/PSTH\">$Pershing Square Tontine Holdings(PSTH)$</a>Whata bad choice of stock to buy&nbsp;","text":"$Pershing Square Tontine Holdings(PSTH)$Whata bad choice of stock to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171000582","isVote":1,"tweetType":1,"viewCount":184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144899380,"gmtCreate":1626273911940,"gmtModify":1631890931936,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Isn’t it overvalued atm","listText":"Isn’t it overvalued atm","text":"Isn’t it overvalued atm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144899380","repostId":"1199719131","repostType":2,"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168954774,"gmtCreate":1623947808598,"gmtModify":1631890931942,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168954774","repostId":"1108846547","repostType":4,"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168954379,"gmtCreate":1623947788891,"gmtModify":1631890931948,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Rushing","listText":"Rushing","text":"Rushing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168954379","repostId":"2144690742","repostType":4,"repost":{"id":"2144690742","pubTimestamp":1623942044,"share":"https://www.laohu8.com/m/news/2144690742?lang=&edition=full","pubTime":"2021-06-17 23:00","market":"us","language":"en","title":"Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2144690742","media":"LA Times","summary":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the F","content":"<p><img src=\"https://static.tigerbbs.com/5a6526be3c93006ee9d37664f7f4650b\" tg-width=\"840\" tg-height=\"560\" referrerpolicy=\"no-referrer\">The FDA's decision on Aduhelm sets up a healthcare spending crisis.&nbsp;</p>\n<p>Following a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.</p>\n<p>It's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.</p>\n<p>The latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.</p>\n<blockquote>\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n</blockquote>\n<p>Altarum consultants</p>\n<p>According to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.</p>\n<p>The drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.</p>\n<p>That will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.</p>\n<p>If 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.</p>\n<p>Many Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.</p>\n<p>It gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.</p>\n<p>This isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.</p>\n<p>Those drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.</p>\n<p>But there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,</p>\n<p>But Aduhelm is neither a cure nor a <a href=\"https://laohu8.com/S/AONE\">one</a>-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"</p>\n<p>The organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"</p>\n<p>As bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, <a href=\"https://laohu8.com/S/AONE.U\">one</a> member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.</p>\n<p>The 11-member committee had advised almost unanimously against the approval. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other members also resigned after the FDA ignored the panel's recommendation.</p>\n<p>Alzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.</p>\n<p>Patients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.</p>\n<p>The longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.</p>\n<p>The drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.</p>\n<p>Aaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.</p>\n<p>The FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.</p>\n<p>But it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.</p>\n<p>This story originally appeared in Los Angeles Times.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nColumn: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html><strong>LA Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine ...</p>\n\n<a href=\"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144690742","content_text":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.\nIt's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.\nThe latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.\n\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n\nAltarum consultants\nAccording to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.\nThe drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.\nThat will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.\nIf 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.\nMany Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.\nIt gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.\nThis isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.\nThose drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.\nBut there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,\nBut Aduhelm is neither a cure nor a one-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"\nThe organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"\nAs bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, one member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.\nThe 11-member committee had advised almost unanimously against the approval. Two other members also resigned after the FDA ignored the panel's recommendation.\nAlzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.\nPatients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.\nThe longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.\nThe drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.\nAaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.\nThe FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.\nBut it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.\nThis story originally appeared in Los Angeles Times.","news_type":1},"isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":810470474,"gmtCreate":1629998316898,"gmtModify":1704954426218,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>It’s a good company, it should be doing well, stock prices oversold&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>It’s a good company, it should be doing well, stock prices oversold&nbsp;","text":"$Tiger Brokers(TIGR)$It’s a good company, it should be doing well, stock prices oversold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810470474","isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320431116,"gmtCreate":1615166400135,"gmtModify":1703485072986,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>At $35, Little tiger is trading at a $4.9 billion valuation, which is 28x next 12 months&nbsp;Gross Profit.Assuming growth decreases to 20-40%&nbsp;over the next few&nbsp;years, this implies around a&nbsp;10x in revenue over the next few years. Which means an estimated price of around $60+","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>At $35, Little tiger is trading at a $4.9 billion valuation, which is 28x next 12 months&nbsp;Gross Profit.Assuming growth decreases to 20-40%&nbsp;over the next few&nbsp;years, this implies around a&nbsp;10x in revenue over the next few years. Which means an estimated price of around $60+","text":"$Tiger Brokers(TIGR)$At $35, Little tiger is trading at a $4.9 billion valuation, which is 28x next 12 months Gross Profit.Assuming growth decreases to 20-40% over the next few years, this implies around a 10x in revenue over the next few years. Which means an estimated price of around $60+","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/320431116","isVote":1,"tweetType":1,"viewCount":1962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369151362,"gmtCreate":1614009993256,"gmtModify":1634551530411,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>My current average price is 824 and will be buying more when it drops further.&nbsp;Looking at where this is going I feel like 650-700will be around the corner this week. I have confidence in Tesla and will continue to buy when possible&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>My current average price is 824 and will be buying more when it drops further.&nbsp;Looking at where this is going I feel like 650-700will be around the corner this week. I have confidence in Tesla and will continue to buy when possible&nbsp;","text":"$Tesla Motors(TSLA)$My current average price is 824 and will be buying more when it drops further. Looking at where this is going I feel like 650-700will be around the corner this week. I have confidence in Tesla and will continue to buy when possible","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/369151362","isVote":1,"tweetType":1,"viewCount":793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327146591,"gmtCreate":1616073799513,"gmtModify":1634527383223,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Let’s predict ATH in a few weeks&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Let’s predict ATH in a few weeks&nbsp;","text":"$Tesla Motors(TSLA)$Let’s predict ATH in a few weeks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":1,"link":"https://laohu8.com/post/327146591","isVote":1,"tweetType":1,"viewCount":722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188077689,"gmtCreate":1623418510841,"gmtModify":1634033482911,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Always fighting with Tesla&nbsp;","listText":"Always fighting with Tesla&nbsp;","text":"Always fighting with Tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/188077689","repostId":"2142088242","repostType":2,"isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":871661259,"gmtCreate":1637065470770,"gmtModify":1637065470889,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871661259","repostId":"1196231262","repostType":4,"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874832900,"gmtCreate":1637754442654,"gmtModify":1637754442654,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Even with good earnings this stock might fall … without a doubt back to lows after today&nbsp;","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Even with good earnings this stock might fall … without a doubt back to lows after today&nbsp;","text":"$Futu Holdings Limited(FUTU)$Even with good earnings this stock might fall … without a doubt back to lows after today","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874832900","isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875965738,"gmtCreate":1637595092281,"gmtModify":1637595092281,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock.&nbsp;Example <a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock.&nbsp;Example <a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>","text":"$Tiger Brokers(TIGR)$Assuming a stable earnings report which may cause another sell off as market now sees anything as not growing by huge %as a bad stock. Example $PayPal(PYPL)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875965738","isVote":1,"tweetType":1,"viewCount":3355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849651672,"gmtCreate":1635754422475,"gmtModify":1635754422580,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Hold with conviction.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Hold with conviction.","text":"$Tiger Brokers(TIGR)$Hold with conviction.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849651672","isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852398341,"gmtCreate":1635239465834,"gmtModify":1635239466002,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term&nbsp;","text":"$Tiger Brokers(TIGR)$The main question on everyones mind is will this stock go back to its higherprices? It seems likely in the long term","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852398341","isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841994293,"gmtCreate":1635866844232,"gmtModify":1635866844232,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Slowly but surely","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Slowly but surely","text":"$Tiger Brokers(TIGR)$Slowly but surely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841994293","isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":163905053,"gmtCreate":1623855225372,"gmtModify":1631890931953,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Goodluck is all I can say","listText":"Goodluck is all I can say","text":"Goodluck is all I can say","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/163905053","repostId":"1167260446","repostType":4,"repost":{"id":"1167260446","pubTimestamp":1623854157,"share":"https://www.laohu8.com/m/news/1167260446?lang=&edition=full","pubTime":"2021-06-16 22:35","market":"sh","language":"en","title":"Federal Reserve to announce policy decision at 2 pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=1167260446","media":"finance.yahoo","summary":"The Federal Reserve will announce its latest policy decision this afternoon.\nAlthough the Fed is exp","content":"<p>The Federal Reserve will announce its latest policy decision this afternoon.</p>\n<p>Although the Fed is expected to keep interest rates pinned at near-zero, the central bankmay offer some clues on when it will slow its aggressive asset purchase program.</p>\n<p>Since the depths of the pandemic, the Fed has been snatching up $120 billion a month in U.S Treasuries and agency mortgage-backed securities.</p>\n<p>With inflationary pressures rising and the economy on the path to recovery,some Fed officials said they were eager to have discussionson paring back the pace of the so-called quantitative easing program.</p>\n<p>But the Fed remains concerned about the recovery in the labor market, asMay jobs datashowed the economy is still 7.6 million jobs short of pre-pandemic levels.</p>\n<p>The policy-setting Federal Open Market Committee will release a statement at 2 p.m. ET, alongside a set of economic projections mapping out forecasts for economic indicators like inflation and unemployment.</p>\n<p>Fed Chairman Jerome Powell will then be pressed on the central bank's policy stance at a press conference at 2:30 p.m. ET.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Reserve to announce policy decision at 2 pm ET</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Reserve to announce policy decision at 2 pm ET\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fed-fomc-monetary-policy-decision-june-2021-143205185.html><strong>finance.yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Federal Reserve will announce its latest policy decision this afternoon.\nAlthough the Fed is expected to keep interest rates pinned at near-zero, the central bankmay offer some clues on when it ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fed-fomc-monetary-policy-decision-june-2021-143205185.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://finance.yahoo.com/news/fed-fomc-monetary-policy-decision-june-2021-143205185.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167260446","content_text":"The Federal Reserve will announce its latest policy decision this afternoon.\nAlthough the Fed is expected to keep interest rates pinned at near-zero, the central bankmay offer some clues on when it will slow its aggressive asset purchase program.\nSince the depths of the pandemic, the Fed has been snatching up $120 billion a month in U.S Treasuries and agency mortgage-backed securities.\nWith inflationary pressures rising and the economy on the path to recovery,some Fed officials said they were eager to have discussionson paring back the pace of the so-called quantitative easing program.\nBut the Fed remains concerned about the recovery in the labor market, asMay jobs datashowed the economy is still 7.6 million jobs short of pre-pandemic levels.\nThe policy-setting Federal Open Market Committee will release a statement at 2 p.m. ET, alongside a set of economic projections mapping out forecasts for economic indicators like inflation and unemployment.\nFed Chairman Jerome Powell will then be pressed on the central bank's policy stance at a press conference at 2:30 p.m. ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839366663,"gmtCreate":1629122799952,"gmtModify":1631890931942,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Goes down insanely with any tiny bad news.","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Goes down insanely with any tiny bad news.","text":"$Tesla Motors(TSLA)$Goes down insanely with any tiny bad news.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/839366663","isVote":1,"tweetType":1,"viewCount":493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":846330063,"gmtCreate":1636046810089,"gmtModify":1636046810258,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Seems like shorters want it at $2&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Seems like shorters want it at $2&nbsp;","text":"$Tiger Brokers(TIGR)$Seems like shorters want it at $2","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846330063","isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854013842,"gmtCreate":1635409954996,"gmtModify":1635410387438,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.","text":"$Tiger Brokers(TIGR)$UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeBEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Singapore subsidiary, Tiger Brokers (Singapore) Pte. Ltd. (“TBSPL”), has received approval to be admitted as a CDP Depository Agent.The Company expects to use such approval to provide our clients with a more comprehensive service offering and improve the user experience in Singapore.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854013842","isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":809719213,"gmtCreate":1627392913632,"gmtModify":1631890931934,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Here we go again …","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Here we go again …","text":"$Tesla Motors(TSLA)$Here we go again …","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809719213","isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168954379,"gmtCreate":1623947788891,"gmtModify":1631890931948,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"Rushing","listText":"Rushing","text":"Rushing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168954379","repostId":"2144690742","repostType":4,"repost":{"id":"2144690742","pubTimestamp":1623942044,"share":"https://www.laohu8.com/m/news/2144690742?lang=&edition=full","pubTime":"2021-06-17 23:00","market":"us","language":"en","title":"Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2144690742","media":"LA Times","summary":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the F","content":"<p><img src=\"https://static.tigerbbs.com/5a6526be3c93006ee9d37664f7f4650b\" tg-width=\"840\" tg-height=\"560\" referrerpolicy=\"no-referrer\">The FDA's decision on Aduhelm sets up a healthcare spending crisis.&nbsp;</p>\n<p>Following a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.</p>\n<p>It's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.</p>\n<p>The latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.</p>\n<blockquote>\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n</blockquote>\n<p>Altarum consultants</p>\n<p>According to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.</p>\n<p>The drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.</p>\n<p>That will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.</p>\n<p>If 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.</p>\n<p>Many Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.</p>\n<p>It gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.</p>\n<p>This isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.</p>\n<p>Those drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.</p>\n<p>But there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,</p>\n<p>But Aduhelm is neither a cure nor a <a href=\"https://laohu8.com/S/AONE\">one</a>-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"</p>\n<p>The organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"</p>\n<p>As bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, <a href=\"https://laohu8.com/S/AONE.U\">one</a> member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.</p>\n<p>The 11-member committee had advised almost unanimously against the approval. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other members also resigned after the FDA ignored the panel's recommendation.</p>\n<p>Alzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.</p>\n<p>Patients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.</p>\n<p>The longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.</p>\n<p>The drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.</p>\n<p>Aaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.</p>\n<p>The FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.</p>\n<p>But it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.</p>\n<p>This story originally appeared in Los Angeles Times.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nColumn: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html><strong>LA Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine ...</p>\n\n<a href=\"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144690742","content_text":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.\nIt's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.\nThe latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.\n\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n\nAltarum consultants\nAccording to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.\nThe drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.\nThat will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.\nIf 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.\nMany Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.\nIt gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.\nThis isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.\nThose drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.\nBut there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,\nBut Aduhelm is neither a cure nor a one-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"\nThe organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"\nAs bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, one member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.\nThe 11-member committee had advised almost unanimously against the approval. Two other members also resigned after the FDA ignored the panel's recommendation.\nAlzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.\nPatients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.\nThe longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.\nThe drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.\nAaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.\nThe FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.\nBut it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.\nThis story originally appeared in Los Angeles Times.","news_type":1},"isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":609596374,"gmtCreate":1638292492235,"gmtModify":1638292492235,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>Zero positive catalyst&nbsp;","listText":"<a href=\"https://laohu8.com/S/PYPL\">$PayPal(PYPL)$</a>Zero positive catalyst&nbsp;","text":"$PayPal(PYPL)$Zero positive catalyst","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609596374","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":160135195,"gmtCreate":1623774389617,"gmtModify":1631889475570,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HBM\">$HudBay Minerals(HBM)$</a>Copper prices are falling&nbsp;","listText":"<a href=\"https://laohu8.com/S/HBM\">$HudBay Minerals(HBM)$</a>Copper prices are falling&nbsp;","text":"$HudBay Minerals(HBM)$Copper prices are falling","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160135195","isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":845785121,"gmtCreate":1636368870973,"gmtModify":1636368871085,"author":{"id":"3575032921579900","authorId":"3575032921579900","name":"Junboytennis","avatar":"https://static.tigerbbs.com/6c0afbbf5589f1409868c980c95084e3","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575032921579900","idStr":"3575032921579900"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>short everyday lol","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>short everyday lol","text":"$Tiger Brokers(TIGR)$short everyday lol","images":[{"img":"https://static.tigerbbs.com/91a03489b7b3ee9099c387b3083cface","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845785121","isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}